Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Needham Reiterates Buy on Surmodics, Raises Price Target to $50

Author: Benzinga Newsdesk | August 02, 2023 12:20pm
Needham analyst Mike Matson reiterates Surmodics (NASDAQ:SRDX) with a Buy and raises the price target from $36 to $50.

Posted In: SRDX

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist